What Researchers Did
Researchers surveyed medical directors of North American hyperbaric oxygen facilities to assess the selection criteria used for treating acute carbon monoxide poisoning.
What They Found
Responses were received from 85% of 208 facilities in the United States and Canada, with 89 monoplace and 58 multiplace chambers treating a total of 2,636 patients in 1992. A significant majority of facilities treat patients with coma (98%), transient loss of consciousness (77%), or focal neurologic deficits (94%), regardless of carboxyhemoglobin (COHb) level. While 92% would use HBO for a patient with headache, nausea, and COHb 40%, only 62% utilize a specified minimum COHb level as the sole criterion for asymptomatic patients.
What This Means for Canadian Patients
Canadian patients experiencing acute carbon monoxide poisoning are likely to receive hyperbaric oxygen treatment if they present with severe symptoms such as coma or neurological deficits. However, the specific carboxyhemoglobin level alone may not consistently determine treatment, and criteria can vary between facilities.
Canadian Relevance
This study directly included Canadian hyperbaric oxygen facilities, with responses from 85% of 208 facilities across North America, making its findings directly relevant to Canadian clinical practice.
Study Limitations
The study relies on self-reported survey data, which may not fully reflect the actual application of selection criteria or patient outcomes in practice.